share_log

EFFECT: Others

EFFECT: Others

EFFECT：其他
美股SEC公告 ·  2024/12/09 19:07

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has received notice from the United States Securities and Exchange Commission (SEC) regarding the effectiveness of its S-3 Form. The Form S-3, with file number 333-283449, became effective on December 6, 2024, at 4:30 P.M.This development signifies that the company's registration statement has been approved by the SEC, potentially allowing Conduit Pharmaceuticals to offer and sell securities to the public. The S-3 Form is commonly used by public companies to register securities for future public offerings, providing the company with increased flexibility in accessing capital markets.
Conduit Pharmaceuticals Inc. has received notice from the United States Securities and Exchange Commission (SEC) regarding the effectiveness of its S-3 Form. The Form S-3, with file number 333-283449, became effective on December 6, 2024, at 4:30 P.M.This development signifies that the company's registration statement has been approved by the SEC, potentially allowing Conduit Pharmaceuticals to offer and sell securities to the public. The S-3 Form is commonly used by public companies to register securities for future public offerings, providing the company with increased flexibility in accessing capital markets.
Conduit Pharmaceuticals Inc. 已收到美国证券交易委员会（SEC）关于其 S-3 表格有效性的通知。文件编号为 333-283449 的 S-3 表格于 2024 年 12 月 6 日下午 4:30 生效。这一发展标志着公司的注册声明已获得 SEC 批准，可能允许 Conduit Pharmaceuticals 向公众提供和卖出证券。S-3 表格通常由上市公司用来注册未来的公开发行证券，为公司在获取资本市场的资金提供了更大的灵活性。
Conduit Pharmaceuticals Inc. 已收到美国证券交易委员会（SEC）关于其 S-3 表格有效性的通知。文件编号为 333-283449 的 S-3 表格于 2024 年 12 月 6 日下午 4:30 生效。这一发展标志着公司的注册声明已获得 SEC 批准，可能允许 Conduit Pharmaceuticals 向公众提供和卖出证券。S-3 表格通常由上市公司用来注册未来的公开发行证券，为公司在获取资本市场的资金提供了更大的灵活性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间